Galecto (GLTO) Projected to Post Quarterly Earnings on Friday

Galecto (NASDAQ:GLTO) is projected to issue its quarterly earnings data before the market opens on Friday, March 14th. Analysts expect the company to announce earnings of ($2.97) per share for the quarter.

Galecto Price Performance

Shares of GLTO opened at $4.01 on Wednesday. The firm has a market cap of $5.28 million, a PE ratio of -0.21 and a beta of 1.18. The stock’s fifty day moving average price is $4.85 and its two-hundred day moving average price is $6.93. Galecto has a 1 year low of $3.76 and a 1 year high of $21.06.

About Galecto

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.